32.02
-0.82(-2.50%)
Currency In USD
| Previous Close | 32.84 |
| Open | 32.84 |
| Day High | 32.9 |
| Day Low | 31.47 |
| 52-Week High | 40.28 |
| 52-Week Low | 25.53 |
| Volume | 1.3M |
| Average Volume | 513,486 |
| Market Cap | 1.79B |
| PE | 24.26 |
| EPS | 1.32 |
| Moving Average 50 Days | 36.45 |
| Moving Average 200 Days | 33.13 |
| Change | -0.82 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $2,806.31 as of March 12, 2025 at a share price of $32.02. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $2,000 as of March 12, 2025 at a share price of $32.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Mar 04, 2025 9:30 PM GMT
ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced t
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 27, 2025 1:30 PM GMT
ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
GlobeNewswire Inc.
Feb 18, 2025 9:25 PM GMT
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated with few adverse events, consistent with previously